A fat-soluble piracetam relative that speeds choline uptake, the raw material for the brain's main memory chemical. Small controlled studies suggest better delayed recall, but only where memory was already impaired; healthy adults have never been tested, and almost all evidence came from the two companies that owned it. Side effects look mild; the unregulated supply is the larger hazard. (Full Review)
| Marker | Target | Why |
|---|---|---|
| eGFR | >90 mL/min/1.73 m² | Elimination is almost entirely renal; reduced filtration raises exposure |
| Cystatin C | 0.60–0.90 mg/L | Detects declining filtration earlier than creatinine and is unaffected by muscle mass |
| Serum creatinine | 0.7–1.1 mg/dL (men), 0.6–0.9 mg/dL (women) | Direct input to eGFR and a check on hydration status |
| Platelet count | 200–350 ×10³/µL | Establishes the baseline against which any antiplatelet effect would be judged |
| Prothrombin time / INR | INR 0.9–1.1 in anyone not on an anticoagulant | Detects any additive effect on clotting from the class antiplatelet signal |
| ALT | <25 U/L (men), <20 U/L (women) | Confirms the expected absence of liver involvement, since metabolism is minimal |
| TSH with free T4 | TSH 0.5–2.0 mIU/L; free T4 mid-reference | Thyroid hormone is the one documented class interaction producing confusion and sleep disturbance |
| Homocysteine | <8 µmol/L | Marks depleted choline reserves, which limit availability downstream of the uptake mechanism |
| Delayed-recall score on a validated memory test | No established target; change from the individual's own baseline, tested at the same time of day | The only direct read on whether the intended effect is occurring |
Cadence: Full panel and a validated delayed-recall test at baseline; cognitive test repeated at 4 weeks; kidney function, platelets, and clotting time rechecked at 8–12 weeks; full panel every 6–12 months thereafter, or sooner if bruising, persistent headache, or sleep disruption appears.